Search

Nabiximols

The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (Δ9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors

Volixibat

If approved for use, it will be the first available agent for the treatment of NASH. … According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments

PYM50018

It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

Ceramide NP

It is widely used as a moisturizer in various cosmetic and personal products. Together with ceramide 1, they synergistically improve the skin barrier function in humans [A27232, A27233].

Triazavirin

[A191709,A191625,A191916] It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications.

SYNB1020

It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer

Mivebresib

The usage of the INN stem '-bresib' in the name indicates that Mivebresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic.

4-O-Demethylpenclomedine

Diazepinomicin

It is a proprietary first-in-class small molecule with the potential to treat multiple solid tumours like the well known chemotherapeutics, doxorubicin and mitomycin C.

Cretostimogene grenadenorepvec

It has been engineered to secrete GM-CSF, an immune stimulating hormone, which also serves as the adjuvant in cancer immunotherapy.